AR and neoplasm: Initially, we showed that administration of these antibodies to tumors where hypoxia was already established by continuous AR-targeted therapy (i.e., at the oxygen nadir reached 14 days post initiation of enzalutamide treatment) resulted in a marked delay of LNCaP tumor reoxygenation, increase in MVD and regrowth.